In female-specific malignancies such as TNBC, platinum-resistant ovarian cancer and type II endometrial carcinoma, sustained NRF2 activation is consistently associated with poor outcomes, as illustrated in Figure 4 (38, 39). This evidence concerns the gene NFE2L2 and ovarian cancer.